Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
•
Gastrointestinal Cancers
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
Related Questions
How do you approach repeat SBRT in the abdomen, specifically when considering constraints for bowel and mesenteric vessels?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
What are your top takeaways from ASCO GI 2025?
What is the best way to proceed in anal cancer surveillance if PET avidity of the primary is reduced, but still avid at time point <6 months s/p chemo-RT?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
How would you treat an MMR-proficient T2 N0 low-rectal cancer (measuring 2 cm extending 4-6 cm from the anal verge) in a patient who wishes to preserve his sphincter?
Would 45 Gy to the pelvis be sufficient for a locally advanced rectal cancer that has a complete metabolic response to TNT?
What's your follow up protocol for a near complete response (nCR) in rectal patients considering non-operative management (NOM)?
Are you using vaginal dilators during treatment of rectal cancer to spare anterior vaginal wall, or are you reserving this for anal cancers?
